Tag: acalabrutinib FDA approval

Home / acalabrutinib FDA approval

Categories

Acalabrutinib with bendamustine and rituximab is approved by the USFDA for previously untreated mantle cell lymphoma

On January 16, 2025, the Food and Drug Administration granted conventional approval to acalabrutinib (Calquence, AstraZeneca) in combination with bendamustine and rituximab for adults with previously ...
acalabrutinib-fda-approval

Scan the code